*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
European stocks finished the Tuesday session on a mixed note despite the sell-off endured over the previous three sessions with French and Spanish shares weaker due to concerns around the still quickly rising number of Covid-19 infections in both.
The focus over the coming week will continue to be on the Federal Reserve as its chairman, Jerome Powell, testifies before the US House of Representative's panel on Covid-19.
London’s top-flight index closed in positive territory on Tuesday, steadying after heavy losses in the previous session as investors mulled updates from the likes of Kingfisher and Whitbread.
Analysts at Morgan Stanley expressed a preference for soft drinks within the wider Beverages universe, reiterating their 'overweight' stance for the likes of CCH and Britvic.
Networking technology company Ethernity has signed a contract to provide an Indian telecoms original equipment manufacturer (OEM) with end-to-end system functionality, it announced on Tuesday, to enable up to 360Gbps cell site router (CSR) appliances.
Hikma Pharmaceuticals lowered its guidance for 2020 on Tuesday, following a response letter from the US Food and Drug Administration (FDA) over the abbreviated new drug application for its generic version of GlaxoSmithKline's ‘Advair Diskus’, or fluticasone propionate and salmeterol inhalation powder, it announced on Tuesday.
Iodine and specialty Iofina has signed binding documentation to refinance its entire debt, it announced on Tuesday, by entering into a new loan agreement with the Cincinnati-based US regional bank First Financial Bank.
